



Clinical Trials in Breast Cancer

Guest Editor:

Prof. Dr. Gilles Freyer

1. Medical Oncology Department,
CITOHL, Hospices Civils de Lyon,
69002 Lyon, France
2. Faculté de Médecine et de
Maïeutique Lyon-Sud-Charles
Mérieux, Université Claude
Bernard Lyon 1, 69310 Pierre-
Bénite, France

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editor

Dear Colleagues,

Clinical trials in oncology are still the most important method of improving our knowledge and guiding our daily clinical practice. During the last decade, the number of anticancer drugs, driven by molecularly targeted agents and immunotherapy, has grown exponentially. To date, drug innovation in oncology represents around 50% of the overall drug development in the world. Breast cancer is probably a good example of this dynamic.

The aim of this Special Issue on “Clinical Trials in Breast Cancer” is to describe the current landscape of clinical trials in surgery, radiotherapy, and medical treatments, to address methodological endpoints, and to understand how biomarkers and preclinical modelling can be better integrated.

Prof. Dr. Gilles Freyer
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)